MLICM
JANX icon

Metropolitan Life Insurance Company (MetLife)’s Janux Therapeutics JANX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,004
Closed -$37.8K – 1078
2024
Q1 		$37.8K Hold
1,004
– – ﹤0.01% 1548
2023
Q4 		$10.8K Hold
1,004
– – ﹤0.01% 2156
2023
Q3 		$10.1K Hold
1,004
– – ﹤0.01% 2203
2023
Q2 		$11.9K Hold
1,004
– – ﹤0.01% 2208
2023
Q1 		$12.1K Sell
1,004
-378
-27% -$6.29K ﹤0.01% 2089
2022
Q4 		$18.2K Hold
1,382
– – ﹤0.01% 2066
2022
Q3 		$18.7K Hold
1,382
– – ﹤0.01% 2062
2022
Q2 		$16.9K Hold
1,382
– – ﹤0.01% 2123
2022
Q1 		$19.8K Sell
1,382
-2,629
-66% -$43K ﹤0.01% 2102
2021
Q4 		$79.1K Hold
4,011
– – ﹤0.01% 2598
2021
Q3 		$86.8K Buy
+4,011
New +$115K ﹤0.01% 2604

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s JANX Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Janux Therapeutics (JANX) in Q2 2024, closing a stake of 1,004 shares — an estimated $37.8K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in JANX in Q3 2021 and held it in 11 quarters. The position peaked at $86.8K in Q3 2021. 155 funds tracked by Wall St. Rank hold JANX as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Janux Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,004 Janux Therapeutics shares in Q2 2024, an estimated $37.8K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Janux Therapeutics in Q3 2021 and held it in 11 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Janux Therapeutics position peaked at $86.8K in Q3 2021.
  • 155 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.